TKPYY - Takeda Pharmaceutical Stock Price, News & Analysis

$27.60 -0.12 (-0.43 %)
(As of 11/24/2017 02:26 AM ET)
Previous Close$27.60
Today's Range$27.77 - $27.46
52-Week Range$19.96 - $29.15
Volume26,481 shs
Average Volume42,273 shs
Market Capitalization$43.29 billion
P/E Ratio31.5
Dividend YieldN/A
Beta0.43

About Takeda Pharmaceutical (OTCMKTS:TKPYY)

Takeda Pharmaceutical logoTakeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases, digestive system drugs, hormonal agents, osteoporosis drugs, antibiotic agents, allergy medications, vitamin drops and vaccines, among others. The Healthcare segment manufactures and sells general drugs and medicines, as well as quasi drugs. The Others segment is involved in the manufacture and sale of reagents, clinical diagnostics and chemical products. As of March 31, 2014, the Company had 146 subsidiaries and 17 associated companies.


Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:TKPYY
CUSIPN/A

Debt

Debt-to-Equity Ratio0.46%
Current Ratio1.35%
Quick Ratio1.10%

Price-To-Earnings

Trailing P/E Ratio31.5
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$16.02 billion
Price / Sales2.69
Cash Flow$2.57 per share
Price / Cash10.75
Book Value$10.56 per share
Price / Book2.61

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS$0.95
Net Income$1.06 billion
Net Margins9.39%
Return on Equity7.46%
Return on Assets3.59%

Miscellaneous

EmployeesN/A
Outstanding Shares1,561,620,000

Frequently Asked Questions for Takeda Pharmaceutical (OTCMKTS:TKPYY)

What is Takeda Pharmaceutical's stock symbol?

Takeda Pharmaceutical trades on the OTCMKTS under the ticker symbol "TKPYY."

When will Takeda Pharmaceutical make its next earnings announcement?

Takeda Pharmaceutical is scheduled to release their next quarterly earnings announcement on Wednesday, February, 7th 2018. View Earnings Estimates for Takeda Pharmaceutical.

Who are some of Takeda Pharmaceutical's key competitors?

Who are Takeda Pharmaceutical's key executives?

Takeda Pharmaceutical's management team includes the folowing people:

  • Masahiro Sakane, Independent Chairman of the Executive Board (Age 76)
  • Christophe Weber, President, Chief Executive Officer, Representative Director (Age 50)
  • Andrew S. Plump, Chief Medical & Scientific Officer, Director (Age 52)
  • Masato Iwasaki, President of Japan Pharma Business Unit, Director (Age 58)
  • Yasuhiko Yamanaka, Director (Age 61)
  • Emiko Azuma, Independent Director (Age 58)
  • Jean-Luc Butel, Independent Director (Age 60)
  • Yoshiaki Fujimori, Independent Director (Age 66)
  • Koji Hatsukawa, Independent Director (Age 66)

How do I buy Takeda Pharmaceutical stock?

Shares of Takeda Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Takeda Pharmaceutical's stock price today?

One share of Takeda Pharmaceutical stock can currently be purchased for approximately $27.60.

How big of a company is Takeda Pharmaceutical?

Takeda Pharmaceutical has a market capitalization of $43.29 billion and generates $16.02 billion in revenue each year. The company earns $1.06 billion in net income (profit) each year or $0.95 on an earnings per share basis.

How can I contact Takeda Pharmaceutical?

Takeda Pharmaceutical's mailing address is 1-1 Doshomachi 4-chome Chuo-ku, Osaka M0, 540-8645. The company can be reached via phone at 816-6204-2111 or via email at [email protected]


MarketBeat Community Rating for Takeda Pharmaceutical (TKPYY)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  42 (Vote Outperform)
Underperform Votes:  61 (Vote Underperform)
Total Votes:  103
MarketBeat's community ratings are surveys of what our community members think about Takeda Pharmaceutical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Takeda Pharmaceutical (OTCMKTS:TKPYY)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for Takeda Pharmaceutical (OTCMKTS:TKPYY)

Price Target History for Takeda Pharmaceutical (OTCMKTS:TKPYY)

Analysts' Ratings History for Takeda Pharmaceutical (OTCMKTS:TKPYY)

Show:
DateFirmActionRatingPrice TargetDetails
1/31/2017Canaccord GenuityReiterated RatingBuyView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for Takeda Pharmaceutical (OTCMKTS:TKPYY)

Earnings by Quarter for Takeda Pharmaceutical (OTCMKTS:TKPYY)

Earnings History by Quarter for Takeda Pharmaceutical (OTCMKTS TKPYY)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/7/2018        
8/1/2014$0.21$4.02 billionViewN/AView Earnings Details
2/5/2014Q4$0.29ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Takeda Pharmaceutical (OTCMKTS:TKPYY)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Takeda Pharmaceutical (OTCMKTS:TKPYY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Takeda Pharmaceutical (OTCMKTS TKPYY)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Takeda Pharmaceutical (OTCMKTS TKPYY)

Source:
DateHeadline
Takeda Pharmaceutical (TKPYY) Presents At Jefferies 2017 London Healthcare Conference - SlideshowTakeda Pharmaceutical (TKPYY) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
seekingalpha.com - November 18 at 9:26 AM
The Chicago Tribune Names Takeda Pharmaceuticals U.S.A., Inc. A Workplace Achiever of the Chicago Area 2017 Top Workplaces AwardThe Chicago Tribune Names Takeda Pharmaceuticals U.S.A., Inc. A Workplace Achiever of the Chicago Area 2017 Top Workplaces Award
finance.yahoo.com - November 11 at 2:37 PM
Takeda, Lundbeck and Advocate Health Care Research Study Aims to Enhance Patient-Provider Engagement in Major Depressive Disorder Treatment using Digital TechnologyTakeda, Lundbeck and Advocate Health Care Research Study Aims to Enhance Patient-Provider Engagement in Major Depressive Disorder Treatment using Digital Technology
finance.yahoo.com - November 7 at 3:26 PM
ETFs with exposure to Takeda Pharmaceutical Co., Ltd. : November 1, 2017ETFs with exposure to Takeda Pharmaceutical Co., Ltd. : November 1, 2017
finance.yahoo.com - November 2 at 9:51 AM
Meta-Analysis Using Real-World Data Evaluates Safety Profile of Entyvio® (vedolizumab) in Patients with Moderate to Severe Ulcerative Colitis or Crohns DiseaseMeta-Analysis Using Real-World Data Evaluates Safety Profile of Entyvio® (vedolizumab) in Patients with Moderate to Severe Ulcerative Colitis or Crohn's Disease
finance.yahoo.com - November 1 at 9:39 AM
New Post-Hoc Analyses Report Early Symptomatic Improvement in Moderately to Severely Active Ulcerative Colitis or Crohns Disease Patients Taking Entyvio® (vedolizumab), Particularly in Biologic-Naïve PatientsNew Post-Hoc Analyses Report Early Symptomatic Improvement in Moderately to Severely Active Ulcerative Colitis or Crohn's Disease Patients Taking Entyvio® (vedolizumab), Particularly in Biologic-Naïve Patients
finance.yahoo.com - October 17 at 8:07 AM
Takeda Donates $100,000 to Local, Regional Charities as Part of Companys Takeda Cares Day EventTakeda Donates $100,000 to Local, Regional Charities as Part of Company's Takeda Cares Day Event
finance.yahoo.com - October 7 at 9:09 AM
Takeda Welcomes The Honorable Susana Mendoza As Guest Speaker At Deerfield Headquarters To Celebrate Companys Commitment to Latino CultureTakeda Welcomes The Honorable Susana Mendoza As Guest Speaker At Deerfield Headquarters To Celebrate Company's Commitment to Latino Culture
finance.yahoo.com - October 6 at 11:23 AM
Takeda Named To 2017 Working Mother "100 Best Companies" For Leadership In Family Benefits And Paid LeaveTakeda Named To 2017 Working Mother "100 Best Companies" For Leadership In Family Benefits And Paid Leave
finance.yahoo.com - October 3 at 1:31 PM
Takeda Pharmaceutical Co., Ltd. :TKPYY-US: Earnings Analysis: Q1, 2018 By the Numbers : September 20, 2017Takeda Pharmaceutical Co., Ltd. :TKPYY-US: Earnings Analysis: Q1, 2018 By the Numbers : September 20, 2017
finance.yahoo.com - September 23 at 10:02 AM
ETFs with exposure to Takeda Pharmaceutical Co., Ltd. : September 22, 2017ETFs with exposure to Takeda Pharmaceutical Co., Ltd. : September 22, 2017
finance.yahoo.com - September 23 at 10:02 AM
[$$] Takeda Pharmaceutical’s CEO Prescribes Stability After Rough Start[$$] Takeda Pharmaceutical’s CEO Prescribes Stability After Rough Start
finance.yahoo.com - September 6 at 9:12 AM
We are in recovery mode: Takeda CEOWe are in recovery mode: Takeda CEO
finance.yahoo.com - September 5 at 9:13 AM
We want to globalize our products and our company, Takeda Pharmaceutical CEO saysWe want to globalize our products and our company, Takeda Pharmaceutical CEO says
finance.yahoo.com - September 5 at 9:13 AM
[$$] Takeda Pharmaceutical Prescribes Stability After Rough Start[$$] Takeda Pharmaceutical Prescribes Stability After Rough Start
finance.yahoo.com - September 5 at 9:13 AM
AstraZeneca recruits Takeda to co-develop Parkinsons candidate MEDI1341, deal value up to $400MAstraZeneca recruits Takeda to co-develop Parkinson's candidate MEDI1341, deal value up to $400M
seekingalpha.com - August 30 at 10:09 AM
[$$] Samsung jumps into risky but lucrative original drugs market[$$] Samsung jumps into risky but lucrative original drugs market
finance.yahoo.com - August 21 at 4:16 AM
[$$] Samsung in Bold Bid to Concoct New Drugs[$$] Samsung in Bold Bid to Concoct New Drugs
finance.yahoo.com - August 20 at 11:14 PM
How Celgene’s Pomalyst Is Positioned after 2Q17How Celgene’s Pomalyst Is Positioned after 2Q17
finance.yahoo.com - August 10 at 8:43 AM
ETFs with exposure to Takeda Pharmaceutical Co., Ltd. : August 4, 2017ETFs with exposure to Takeda Pharmaceutical Co., Ltd. : August 4, 2017
finance.yahoo.com - August 4 at 9:03 AM
Takeda and Marvel Custom Solutions Debut the Full IBD Unmasked Graphic Novel Featuring a Team of Inflammatory Bowel Disease (IBD) Super HeroesTakeda and Marvel Custom Solutions Debut the Full IBD Unmasked Graphic Novel Featuring a Team of Inflammatory Bowel Disease (IBD) Super Heroes
finance.yahoo.com - August 2 at 7:49 AM
Walthams Tesaro grabs $100M in cancer drug partnership with TakedaWaltham's Tesaro grabs $100M in cancer drug partnership with Takeda
finance.yahoo.com - July 28 at 8:51 AM
Nikkei falls to more than 1-week lows as cyclical stocks weigh; Toshiba jumpsNikkei falls to more than 1-week lows as cyclical stocks weigh; Toshiba jumps
finance.yahoo.com - July 18 at 8:58 AM
Takeda Pharmaceutical Company Limited -- Moodys assigns A1 rating to Takeda Pharmaceuticals USD notesTakeda Pharmaceutical Company Limited -- Moody's assigns A1 rating to Takeda Pharmaceutical's USD notes
finance.yahoo.com - July 13 at 10:29 AM
ETFs with exposure to Takeda Pharmaceutical Co., Ltd. : July 5, 2017ETFs with exposure to Takeda Pharmaceutical Co., Ltd. : July 5, 2017
finance.yahoo.com - July 6 at 1:03 PM
Takeda Pharmaceutical Co., Ltd. :TKPYY-US: Earnings Analysis: Q4, 2017 By the Numbers : July 4, 2017Takeda Pharmaceutical Co., Ltd. :TKPYY-US: Earnings Analysis: Q4, 2017 By the Numbers : July 4, 2017
finance.yahoo.com - July 4 at 6:47 PM
Takeda, Seattle Genetics Report Positive Results From Phase 3 ECHELON-1 TrialTakeda, Seattle Genetics Report Positive Results From Phase 3 ECHELON-1 Trial
www.rttnews.com - June 26 at 7:47 AM
BRIEF-Takeda announces FDA accelerated approval of ALUNBRIGBRIEF-Takeda announces FDA accelerated approval of ALUNBRIG
www.reuters.com - April 28 at 10:51 PM
BRIEF-Takeda Pharmaceutical says splitting off partial Takeda Development Center Japan businesses to unit and plans JV with PRA Health SciencesBRIEF-Takeda Pharmaceutical says splitting off partial Takeda Development Center Japan businesses to unit and plans JV with PRA Health Sciences
www.reuters.com - April 7 at 1:01 PM
Takeda’s Dengue Vaccine Candidate Elicited Broad Immune Responses in Children and Adolescents Living in Dengue-Endemic Areas; Interim Phase 2 Analysis Published in The Lancet Infectious DiseasesTakeda’s Dengue Vaccine Candidate Elicited Broad Immune Responses in Children and Adolescents Living in Dengue-Endemic Areas; Interim Phase 2 Analysis Published in The Lancet Infectious Diseases
us.rd.yahoo.com - March 30 at 5:28 AM
Takeda Announces Ricardo Marek as New President of Emerging Markets Business UnitTakeda Announces Ricardo Marek as New President of Emerging Markets Business Unit
au.finance.yahoo.com - March 30 at 5:28 AM
Takeda and TiGenix Report New Data Highlighting Maintenance of Long-Term Remission of Complex Perianal Fistulas in Crohn’s Disease Patients with Cx601Takeda and TiGenix Report New Data Highlighting Maintenance of Long-Term Remission of Complex Perianal Fistulas in Crohn’s Disease Patients with Cx601
us.rd.yahoo.com - February 17 at 7:03 PM
Takeda Presents $1 Million Gift to the Koch Institute for Integrative Cancer Research at MIT to Support Immuno-oncology ResearchTakeda Presents $1 Million Gift to the Koch Institute for Integrative Cancer Research at MIT to Support Immuno-oncology Research
au.finance.yahoo.com - February 9 at 6:11 AM
[$$] US biotech Ovid to develop Takeda epilepsy drug in outsourcing tie-up[$$] US biotech Ovid to develop Takeda epilepsy drug in outsourcing tie-up
www.ft.com - January 19 at 4:55 AM
Takeda and Ovid Therapeutics Announce Innovative Clinical Development and Commercialization Collaboration for TAK-935 in Rare Pediatric EpilepsiesTakeda and Ovid Therapeutics Announce Innovative Clinical Development and Commercialization Collaboration for TAK-935 in Rare Pediatric Epilepsies
au.finance.yahoo.com - January 19 at 4:54 AM
Maverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement TherapiesMaverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement Therapies
us.rd.yahoo.com - January 12 at 3:20 AM
Takeda Buys Ariad For $5.2 Billion: A Good Deal?Takeda Buys Ariad For $5.2 Billion: A Good Deal?
blogs.barrons.com - January 10 at 2:12 AM
Takeda To Buy ARIAD For $24.00/shr; Accretive To FY18 Underlying Core EarningsTakeda To Buy ARIAD For $24.00/shr; Accretive To FY18 Underlying Core Earnings
www.nasdaq.com - January 10 at 2:12 AM
UW spinout wins $35M deal to develop therapy for celiac diseaseUW spinout wins $35M deal to develop therapy for celiac disease
www.bizjournals.com - January 7 at 6:02 AM
Takeda and PvP Biologics Announce Development Agreement around Novel Therapeutic for Celiac DiseaseTakeda and PvP Biologics Announce Development Agreement around Novel Therapeutic for Celiac Disease
us.rd.yahoo.com - January 6 at 6:09 AM
Valeant: Avoid Post Salix/Takeda Deal BreakdownValeant: Avoid Post Salix/Takeda Deal Breakdown
seekingalpha.com - December 2 at 11:08 AM
Cerevance Launched with New Technology, Drug Portfolio and $36M in Cash to Tackle Brain DiseasesCerevance Launched with New Technology, Drug Portfolio and $36M in Cash to Tackle Brain Diseases
au.finance.yahoo.com - December 2 at 11:08 AM
Valeant Stock Plunges 11% on Failed Salix Sale (VRX)Valeant Stock Plunges 11% on Failed Salix Sale (VRX)
www.investopedia.com - December 1 at 9:47 AM
Valeant Said to Keep Salix After Takeda Deal Falls ApartValeant Said to Keep Salix After Takeda Deal Falls Apart
www.bloomberg.com - November 30 at 11:36 PM
Takeda to Invest More Than 100 Million Euros in Dengue Vaccine Manufacturing Plant in GermanyTakeda to Invest More Than 100 Million Euros in Dengue Vaccine Manufacturing Plant in Germany
au.finance.yahoo.com - November 30 at 10:22 AM
NINLARO™ (ixazomib) Receives Conditional Approval from the European Commission to Treat Multiple MyelomaNINLARO™ (ixazomib) Receives Conditional Approval from the European Commission to Treat Multiple Myeloma
us.rd.yahoo.com - November 29 at 10:51 AM
3:19 am Takeda Pharma receives conditional approval for NINLARO from the European Commission3:19 am Takeda Pharma receives conditional approval for NINLARO from the European Commission
us.rd.yahoo.com - November 29 at 10:51 AM
Valeant: Salix Rumors Send Sum-Of-The Parts Valuation Below $1Valeant: Salix Rumors Send Sum-Of-The Parts Valuation Below $1
seekingalpha.com - November 24 at 7:48 PM
Takeda and the New York Academy of Sciences to Honor Commitment to Innovation in Key Areas of Therapeutic FocusTakeda and the New York Academy of Sciences to Honor Commitment to Innovation in Key Areas of Therapeutic Focus
au.finance.yahoo.com - November 10 at 11:27 AM
Valeant: $50-$70 After Salix SaleValeant: $50-$70 After Salix Sale
seekingalpha.com - November 3 at 7:55 PM

Social Media

Financials

Financials are not available for this stock.

Chart

Takeda Pharmaceutical (OTCMKTS TKPYY) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.